Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 228.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 556.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity. |
Targets&IC50 | BCR-ABL1:7 nM (IC50) |
Synonyms | K-0706 |
Molecular Weight | 453.92 |
Formula | C27H20ClN3O2 |
CAS No. | 1388803-90-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (55.07 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vodobatinib 1388803-90-4 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl myeloid Inhibitor inhibit K 0706 K-0706 chronic Bcr-Abl1 K0706 leukemia TKI inhibitor